GH Research (NASDAQ:GHRS) Coverage Initiated by Analysts at Royal Bank of Canada

Research analysts at Royal Bank of Canada started coverage on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $31.00 price target on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 193.84% from the company’s current price.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald initiated coverage on GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 target price for the company. Canaccord Genuity Group cut their target price on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Finally, Stifel Nicolaus increased their target price on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, GH Research presently has an average rating of “Buy” and an average target price of $30.67.

GH Research Stock Performance

GHRS stock opened at $10.55 on Friday. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The business’s 50-day moving average is $10.73 and its two-hundred day moving average is $9.20. The company has a market cap of $548.90 million, a price-to-earnings ratio of -13.35 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. Equities analysts predict that GH Research will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

A number of institutional investors and hedge funds have recently modified their holdings of GHRS. Lynx1 Capital Management LP boosted its holdings in shares of GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after purchasing an additional 663,100 shares during the period. Diadema Partners LP bought a new stake in shares of GH Research during the 4th quarter worth approximately $711,000. RA Capital Management L.P. lifted its stake in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after acquiring an additional 85,000 shares during the last quarter. Woodline Partners LP lifted its stake in shares of GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after acquiring an additional 41,711 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of GH Research during the 4th quarter worth approximately $145,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).